Published in Heart Fail Rev on July 01, 2015
Microglia-Induced Maladaptive Plasticity Can Be Modulated by Neuropeptides In Vivo. Neural Plast (2015) 0.75
A promoter polymorphism in APJ gene is significantly associated with blood pressure changes and hypertension risk in Chinese women. Oncotarget (2016) 0.75
Prospective evaluation of the diagnostic value of plasma apelin 12 levels for differentiating patients with moyamoya and intracranial atherosclerotic diseases. Sci Rep (2017) 0.75
Cardiac excitation-contraction coupling. Nature (2002) 18.48
A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res (2000) 6.78
Control of mouse cardiac morphogenesis and myogenesis by transcription factor MEF2C. Science (1997) 5.54
Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun (1998) 4.08
Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem (2002) 3.81
Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev (2000) 3.40
Mitochondrial deficiency and cardiac sudden death in mice lacking the MEF2A transcription factor. Nat Med (2002) 3.31
A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene (1993) 2.59
Angiotensin II signal transduction through the AT1 receptor: novel insights into mechanisms and pathophysiology. Clin Sci (Lond) (2007) 2.39
Interleukin-1beta and tumor necrosis factor-alpha decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro. Circ Res (2000) 2.36
Angiostatin inhibits coronary angiogenesis during impaired production of nitric oxide. Circulation (2002) 2.35
The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo. Cardiovasc Res (2005) 2.24
Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circ Res (2002) 2.15
Characterization of apelin, the ligand for the APJ receptor. J Neurochem (2000) 2.11
The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism. Regul Pept (2001) 2.07
Angiotensin-(1-9) reverses experimental hypertension and cardiovascular damage by inhibition of the angiotensin converting enzyme/Ang II axis. J Hypertens (2014) 2.04
Apelin, the ligand for the endothelial G-protein-coupled receptor, APJ, is a potent angiogenic factor required for normal vascular development of the frog embryo. Dev Biol (2006) 2.04
Multiple facets of NF-κB in the heart: to be or not to NF-κB. Circ Res (2011) 2.01
Regulatory roles for APJ, a seven-transmembrane receptor related to angiotensin-type 1 receptor in blood pressure in vivo. J Biol Chem (2004) 1.91
Apelin signaling antagonizes Ang II effects in mouse models of atherosclerosis. J Clin Invest (2008) 1.89
Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. Circulation (2010) 1.77
Apelin modulates aortic vascular tone via endothelial nitric oxide synthase phosphorylation pathway in diabetic mice. Cardiovasc Res (2007) 1.76
Emerging roles of apelin in biology and medicine. Pharmacol Ther (2005) 1.73
Spatial and temporal role of the apelin/APJ system in the caliber size regulation of blood vessels during angiogenesis. EMBO J (2008) 1.72
Apelin-APJ signaling is a critical regulator of endothelial MEF2 activation in cardiovascular development. Circ Res (2013) 1.68
APJ acts as a dual receptor in cardiac hypertrophy. Nature (2012) 1.62
Disruption of PPARγ/β-catenin-mediated regulation of apelin impairs BMP-induced mouse and human pulmonary arterial EC survival. J Clin Invest (2011) 1.60
Apelin is a novel angiogenic factor in retinal endothelial cells. Biochem Biophys Res Commun (2004) 1.59
Immunocytochemical localization of the endogenous vasoactive peptide apelin to human vascular and endocardial endothelial cells. Regul Pept (2004) 1.58
The first minutes of reperfusion: a window of opportunity for cardioprotection. Cardiovasc Res (2004) 1.58
Apelin, a potent diuretic neuropeptide counteracting vasopressin actions through inhibition of vasopressin neuron activity and vasopressin release. Proc Natl Acad Sci U S A (2004) 1.58
Nitric oxide and angiogenesis. Circulation (2002) 1.56
Molecular and functional characteristics of APJ. Tissue distribution of mRNA and interaction with the endogenous ligand apelin. J Biol Chem (2000) 1.54
Venous dilator effect of apelin, an endogenous peptide ligand for the orphan APJ receptor, in conscious rats. Eur J Pharmacol (2003) 1.50
Dilated cardiomyopathy caused by aberrant endoplasmic reticulum quality control in mutant KDEL receptor transgenic mice. Mol Cell Biol (2004) 1.48
Preconditioning and postconditioning: united at reperfusion. Pharmacol Ther (2007) 1.45
[(125)I]-(Pyr(1))Apelin-13 is a novel radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasoconstrictor role in man. Br J Pharmacol (2001) 1.40
Apelin has in vivo inotropic effects on normal and failing hearts. Circulation (2004) 1.37
Endogenous regulation of cardiovascular function by apelin-APJ. Am J Physiol Heart Circ Physiol (2009) 1.34
The myocardial Na(+)-H(+) exchange: structure, regulation, and its role in heart disease. Circ Res (1999) 1.34
Vascular effects of apelin in vivo in man. J Am Coll Cardiol (2008) 1.33
Low increase in cGMP induced by organic nitrates and nitrovasodilators improves contractile response of rat ventricular myocytes. Circ Res (1996) 1.31
[Pyr1]apelin-13 identified as the predominant apelin isoform in the human heart: vasoactive mechanisms and inotropic action in disease. Hypertension (2009) 1.31
Apelin signalling: a promising pathway from cloning to pharmacology. Cell Signal (2005) 1.31
Apelin-13 and apelin-36 exhibit direct cardioprotective activity against ischemia-reperfusion injury. Basic Res Cardiol (2007) 1.27
ELABELA: a hormone essential for heart development signals via the apelin receptor. Dev Cell (2013) 1.26
Hypoxia inducible factor regulates the cardiac expression and secretion of apelin. FASEB J (2007) 1.24
Nitric oxide and cardiac function. Life Sci (2007) 1.23
Direct effects of apelin on cardiomyocyte contractility and electrophysiology. Biochem Biophys Res Commun (2007) 1.23
Apelin induces enlarged and nonleaky blood vessels for functional recovery from ischemia. Blood (2010) 1.22
Role of angiotensin II in cardiovascular disease therapeutic implications of more than a century of research. J Renin Angiotensin Aldosterone Syst (2006) 1.19
Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure. Biochem Biophys Res Commun (2003) 1.19
The apelin-APJ system in heart failure: pathophysiologic relevance and therapeutic potential. Biochem Pharmacol (2008) 1.18
Xapelin and Xmsr are required for cardiovascular development in Xenopus laevis. Dev Biol (2006) 1.18
Apelin protects heart against ischemia/reperfusion injury in rat. Peptides (2009) 1.15
Adrenergic signaling polymorphisms and their impact on cardiovascular disease. Physiol Rev (2010) 1.15
Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure. Eur J Heart Fail (2006) 1.12
Recombinant superoxide dismutase reduces oxygen free radical concentrations in reperfused myocardium. J Clin Invest (1987) 1.12
Expression of a new G protein-coupled receptor X-msr is associated with an endothelial lineage in Xenopus laevis. Mech Dev (1996) 1.12
Apelin stimulates myosin light chain phosphorylation in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol (2006) 1.10
Apelin-13 protects the heart against ischemia-reperfusion injury through inhibition of ER-dependent apoptotic pathways in a time-dependent fashion. Am J Physiol Heart Circ Physiol (2011) 1.08
Amino acid sequence and embryonic expression of msr/apj, the mouse homolog of Xenopus X-msr and human APJ. Mech Dev (1999) 1.07
Apelin reduces myocardial reperfusion injury independently of PI3K/Akt and P70S6 kinase. Regul Pept (2007) 1.06
Apelin prevents cardiac fibroblast activation and collagen production through inhibition of sphingosine kinase 1. Eur Heart J (2011) 1.06
Apelin is a potent activator of tumour neoangiogenesis. Oncogene (2007) 1.06
Expression of the murine msr/apj receptor and its ligand apelin is upregulated during formation of the retinal vessels. Mech Dev (2002) 1.06
Apelin protects myocardial injury induced by isoproterenol in rats. Regul Pept (2005) 1.05
Loss of Apelin exacerbates myocardial infarction adverse remodeling and ischemia-reperfusion injury: therapeutic potential of synthetic Apelin analogues. J Am Heart Assoc (2013) 1.05
The msr/apj gene encoding the apelin receptor is an early and specific marker of the venous phenotype in the retinal vasculature. Gene Expr Patterns (2003) 1.00
Apelin suppresses apoptosis of human osteoblasts. Apoptosis (2007) 1.00
The apelin receptor inhibits the angiotensin II type 1 receptor via allosteric trans-inhibition. Br J Pharmacol (2013) 0.98
Apelin stimulates proliferation and suppresses apoptosis of mouse osteoblastic cell line MC3T3-E1 via JNK and PI3-K/Akt signaling pathways. Peptides (2006) 0.97
Apelin increases cardiac contractility via protein kinase Cε- and extracellular signal-regulated kinase-dependent mechanisms. PLoS One (2014) 0.97
Apelin enhances directed cardiac differentiation of mouse and human embryonic stem cells. PLoS One (2012) 0.97
Protective effect of apelin on cultured rat bone marrow mesenchymal stem cells against apoptosis. Stem Cell Res (2011) 0.96
Apelin protects against cardiomyocyte apoptosis induced by glucose deprivation. Chin Med J (Engl) (2009) 0.96
The apelinergic system: the role played in human physiology and pathology and potential therapeutic applications. Arq Bras Cardiol (2008) 0.96
Central and peripheral cardiovascular actions of apelin in conscious rats. Regul Pept (2005) 0.95
Angiotensin-(1-9) attenuates cardiac fibrosis in the stroke-prone spontaneously hypertensive rat via the angiotensin type 2 receptor. Hypertension (2011) 0.95
Apelin is a positive regulator of ACE2 in failing hearts. J Clin Invest (2013) 0.95
Myocardial fibrosis in response to Angiotensin II is preceded by the recruitment of mesenchymal progenitor cells. Lab Invest (2010) 0.94
Apelin increases contractility in failing cardiac muscle. Eur J Pharmacol (2006) 0.94
Reciprocal regulation of plasma apelin and vasopressin by osmotic stimuli. J Am Soc Nephrol (2008) 0.93
Apelin suppresses apoptosis of human vascular smooth muscle cells via APJ/PI3-K/Akt signaling pathways. Amino Acids (2010) 0.91
Regulation of cardiac contraction and relaxation. Circulation (2000) 0.90
ERK1/2 mediates lung adenocarcinoma cell proliferation and autophagy induced by apelin-13. Acta Biochim Biophys Sin (Shanghai) (2013) 0.90
Apelin decreases the SR Ca2+ content but enhances the amplitude of [Ca2+]i transient and contractions during twitches in isolated rat cardiac myocytes. Am J Physiol Heart Circ Physiol (2008) 0.89
Sustained cardiovascular actions of APJ agonism during renin-angiotensin system activation and in patients with heart failure. Circ Heart Fail (2013) 0.89
Apelin-36, a potent peptide, protects against ischemic brain injury by activating the PI3K/Akt pathway. Neurochem Int (2013) 0.89
Apelin-13 protects the brain against ischemia/reperfusion injury through activating PI3K/Akt and ERK1/2 signaling pathways. Neurosci Lett (2014) 0.88
Modulation of the apelin/APJ system in heart failure and atherosclerosis in man. Br J Pharmacol (2010) 0.87
Increased β-adrenergic inotropy in ventricular myocardium from Trpm4-/- mice. Circ Res (2013) 0.87
Apelin-13 protects the brain against ischemic reperfusion injury and cerebral edema in a transient model of focal cerebral ischemia. J Mol Neurosci (2012) 0.87
Temporal changes in myocardial salvage kinases during reperfusion following ischemia: studies involving the cardioprotective adipocytokine apelin. Cardiovasc Drugs Ther (2007) 0.86
Apelin-13 limits infarct size and improves cardiac postischemic mechanical recovery only if given after ischemia. Am J Physiol Heart Circ Physiol (2011) 0.86
Cardioprotective effect of apelin-13 on cardiac performance and remodeling in end-stage heart failure. Circ J (2011) 0.86
Apelin and pulmonary hypertension. Pulm Circ (2011) 0.86
Angiotensin-(1-7) and angiotensin-(1-9): function in cardiac and vascular remodelling. Clin Sci (Lond) (2014) 0.85
Non-activated APJ suppresses the angiotensin II type 1 receptor, whereas apelin-activated APJ acts conversely. Hypertens Res (2011) 0.84
Interactions between apelin and angiotensin II on rat portal vein. J Renin Angiotensin Aldosterone Syst (2006) 0.84
Cardiac stem cells possess growth factor-receptor systems that after activation regenerate the infarcted myocardium, improving ventricular function and long-term survival. Circ Res (2005) 3.93
Cardiac stem cells delivered intravascularly traverse the vessel barrier, regenerate infarcted myocardium, and improve cardiac function. Proc Natl Acad Sci U S A (2005) 3.64
Local activation or implantation of cardiac progenitor cells rescues scarred infarcted myocardium improving cardiac function. Circ Res (2008) 3.07
Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol (2007) 2.51
Exogenous high-mobility group box 1 protein induces myocardial regeneration after infarction via enhanced cardiac C-kit+ cell proliferation and differentiation. Circ Res (2005) 2.32
Chronic hypoxia: a model for cyanotic congenital heart defects. J Thorac Cardiovasc Surg (2002) 2.11
Post-conditioning induced cardioprotection requires signaling through a redox-sensitive mechanism, mitochondrial ATP-sensitive K+ channel and protein kinase C activation. Basic Res Cardiol (2006) 2.08
Cardioprotection: a radical view Free radicals in pre and postconditioning. Biochim Biophys Acta (2009) 1.29
Nitroxyl affords thiol-sensitive myocardial protective effects akin to early preconditioning. Free Radic Biol Med (2003) 1.28
A peptide inhibitor of c-Jun NH2-terminal kinase reduces myocardial ischemia-reperfusion injury and infarct size in vivo. Am J Physiol Heart Circ Physiol (2006) 1.08
Intermittent activation of bradykinin B2 receptors and mitochondrial KATP channels trigger cardiac postconditioning through redox signaling. Cardiovasc Res (2007) 1.08
Oxidation and haem loss kinetics of poly(ethylene glycol)-conjugated haemoglobin (MP4): dissociation between in vitro and in vivo oxidation rates. Biochem J (2006) 1.07
Post-conditioning reduces infarct size in the isolated rat heart: role of coronary flow and pressure and the nitric oxide/cGMP pathway. Basic Res Cardiol (2005) 1.06
Hypoxia: unique myocardial morphology? J Thorac Cardiovasc Surg (2004) 1.03
Partial persistence of exercise-induced myocardial angiogenesis following 4-week detraining in the rat. Histochem Cell Biol (2008) 1.01
Mild exercise training, cardioprotection and stress genes profile. Eur J Appl Physiol (2007) 0.98
Chronic and intermittent hypoxia induce different degrees of myocardial tolerance to hypoxia-induced dysfunction. Exp Biol Med (Maywood) (2002) 0.97
Kinetics of NO and O2 binding to a maleimide poly(ethylene glycol)-conjugated human haemoglobin. Biochem J (2004) 0.97
Acid-base balance at exercise in normoxia and in chronic hypoxia. Revisiting the "lactate paradox". Eur J Appl Physiol (2003) 0.96
D-aspartic acid in the nervous system of Aplysia limacina: possible role in neurotransmission. J Cell Physiol (2006) 0.95
MAPK/Erk-dependent phosphorylation of synapsin mediates formation of functional synapses and short-term homosynaptic plasticity. J Cell Sci (2010) 0.95
Effect of contraction frequency on the contractile and noncontractile phases of muscle venous blood flow. J Appl Physiol (1985) (2003) 0.94
The role of PDE5-inhibitors in cardiopulmonary disorders: from basic evidence to clinical development. Curr Med Chem (2007) 0.94
Postconditioning cardioprotection against infarct size and post-ischemic systolic dysfunction is influenced by gender. Basic Res Cardiol (2008) 0.94
Carbamylated erythropoietin ameliorates the metabolic stress induced in vivo by severe chronic hypoxia. Proc Natl Acad Sci U S A (2006) 0.92
Phosphorylation of synapsin domain A is required for post-tetanic potentiation. J Cell Sci (2007) 0.91
Effect of endothelins on the cardiovascular system. J Cardiovasc Med (Hagerstown) (2006) 0.90
Amino acid- and lipid-induced insulin resistance in rat heart: molecular mechanisms. Mol Cell Endocrinol (2002) 0.90
Human recombinant chromogranin A-derived vasostatin-1 mimics preconditioning via an adenosine/nitric oxide signaling mechanism. Am J Physiol Heart Circ Physiol (2007) 0.90
Cellular distribution of Hsp70 expression in rat skeletal muscles. Effects of moderate exercise training and chronic hypoxia. Cell Stress Chaperones (2008) 0.90
Early homing of adult mesenchymal stem cells in normal and infarcted isolated beating hearts. J Cell Mol Med (2008) 0.90
Phosphodiesterase-5 inhibition abolishes neuron apoptosis induced by chronic hypoxia independently of hypoxia-inducible factor-1alpha signaling. Exp Biol Med (Maywood) (2008) 0.89
Chronic in vivo hypoxia in various organs: hypoxia-inducible factor-1alpha and apoptosis. Biochem Biophys Res Commun (2006) 0.89
Gene expression profile of rat left ventricles reveals persisting changes following chronic mild exercise protocol: implications for cardioprotection. BMC Genomics (2009) 0.89
Simultaneous determination of purine nucleotides, their metabolites and beta-nicotinamide adenine dinucleotide in cerebellar granule cells by ion-pair high performance liquid chromatography. Brain Res Brain Res Protoc (2003) 0.89
Impact of the phosphatidylinositide 3-kinase signaling pathway on the cardioprotection induced by intermittent hypoxia. PLoS One (2013) 0.89
Phosphorylation of phosphatidylinositol-3-kinase-protein kinase B and extracellular signal-regulated kinases 1/2 mediate reoxygenation-induced cardioprotection during hypoxia. Exp Biol Med (Maywood) (2010) 0.89
Phosphodiesterase-5 inhibition mimics intermittent reoxygenation and improves cardioprotection in the hypoxic myocardium. PLoS One (2011) 0.88
Phosphorylation by cAMP-dependent protein kinase is essential for synapsin-induced enhancement of neurotransmitter release in invertebrate neurons. J Cell Sci (2004) 0.87
Hyperoxia confers myocardial protection in mechanically ventilated rats through the generation of free radicals and opening of mitochondrial ATP-sensitive potassium channels. Clin Exp Pharmacol Physiol (2008) 0.87
Apelin-13 limits infarct size and improves cardiac postischemic mechanical recovery only if given after ischemia. Am J Physiol Heart Circ Physiol (2011) 0.86
Heart HIF-1alpha and MAP kinases during hypoxia: are they associated in vivo? Exp Biol Med (Maywood) (2007) 0.85
Myocardial impairment in chronic hypoxia is abolished by short aeration episodes: involvement of K+ATP channels. Exp Biol Med (Maywood) (2004) 0.84
Myocardial tolerance to ischemia-reperfusion injury, training intensity and cessation. Eur J Appl Physiol (2010) 0.84
Antitumour activity of melatonin in a mouse model of human prostate cancer: relationship with hypoxia signalling. J Pineal Res (2014) 0.84
Brief reoxygenation episodes during chronic hypoxia enhance posthypoxic recovery of LV function: role of mitogen-activated protein kinase signaling pathways. Basic Res Cardiol (2006) 0.83
Daily reoxygenation decreases myocardial injury and improves post-ischaemic recovery after chronic hypoxia. Eur J Cardiothorac Surg (2009) 0.83
Synaptic functions of invertebrate varicosities: what molecular mechanisms lie beneath. Neural Plast (2012) 0.82
Xanthine oxido-reductase activity in ischemic human and rat intestine. Free Radic Res (2004) 0.82
The effect of bioartificial constructs that mimic myocardial structure and biomechanical properties on stem cell commitment towards cardiac lineage. Biomaterials (2013) 0.82
In vivo up-regulation of the unfolded protein response after hypoxia. Biochim Biophys Acta (2012) 0.82
Inhibition of neurotransmitter release by a nonphysiological target requires protein synthesis and involves cAMP-dependent and mitogen-activated protein kinases. J Neurosci (2004) 0.81
Protein modulation in mouse heart under acute and chronic hypoxia. Proteomics (2011) 0.81
Cytochrome c oxidase expression in chronic and intermittent hypoxia rat gastrocnemius muscle quantitated by CE. Electrophoresis (2006) 0.81
Coronary endothelial dysfunction after ischemia and reperfusion and its prevention by ischemic preconditioning. Ital Heart J (2003) 0.81
Distribution of sensorin immunoreactivity in the central nervous system of Helix pomatia: functional aspects. J Neurosci Res (2004) 0.80
F0F1 ATP synthase activity is differently modulated by coronary reactive hyperemia before and after ischemic preconditioning in the goat. Am J Physiol Heart Circ Physiol (2004) 0.80
[Clinical use of phosphodiesterase-5 inhibitors in cardiopulmonary diseases: from experimental evidence to clinical application]. G Ital Cardiol (Rome) (2010) 0.79
Chronic systemic hypoxia promotes LNCaP prostate cancer growth in vivo. Prostate (2010) 0.79
Expression of carbohydrate-antigen sialyl-Lewis a on colon cancer cells promotes xenograft growth and angiogenesis in nude mice. Int J Biochem Cell Biol (2013) 0.79
Balance of nitric oxide and reactive oxygen species in myocardial reperfusion injury and protection. J Cardiovasc Pharmacol (2013) 0.79
Omega 3 has a beneficial effect on ischemia/reperfusion injury, but cannot reverse the effect of stressful forced exercise. Nutr Metab Cardiovasc Dis (2008) 0.78
Impact of acellular hemoglobin-based oxygen carriers on brain apoptosis in rats. Transfusion (2014) 0.78
Supplementation of creatine and ribose prevents apoptosis in ischemic cardiomyocytes. Cell Physiol Biochem (2011) 0.78
Low-flow ischemia and hypoxia stimulate apoptosis in perfused hearts independently of reperfusion. Cell Physiol Biochem (2002) 0.77
Pentylenetetrazol-induced epileptiform activity affects basal synaptic transmission and short-term plasticity in monosynaptic connections. PLoS One (2013) 0.77
Modulation of the NO/cGMP pathway reduces the vasoconstriction induced by acellular and PEGylated haemoglobin. Biochim Biophys Acta (2008) 0.76
F3/contactin-related proteins in Helix pomatia nervous tissue (HCRPs): distribution and function in neurite growth and neurotransmitter release. J Neurosci Res (2008) 0.76
Autophagy and human parturition: evaluation of LC3 expression in placenta from spontaneous or medically induced onset of labor. Biomed Res Int (2013) 0.76
Comments on point:counterpoint: "the lactate paradox does/does not occur during exercise at high altitude". J Appl Physiol (1985) (2007) 0.75
Role of three adipokines in metabolic syndrome. Pol Arch Med Wewn (2016) 0.75
Ischemic preconditioning changes the pattern of coronary reactive hyperemia regardless of mitochondrial ATP-sensitive K(+) channel blockade. Life Sci (2002) 0.75
Supplementation of creatine and ribose prevents apoptosis and right ventricle hypertrophy in hypoxic hearts. Curr Pharm Des (2013) 0.75
Effects of broad band electromagnetic fields on HSP70 expression and ischemia-reperfusion in rat hearts. Life Sci (2004) 0.75
Effects of nitric oxide donor antioxidants containing the phenol vitamin E substructure and a furoxan moiety on ischemia/reperfusion injury. Arzneimittelforschung (2009) 0.75